Heart failure hope for Novartis first-in-class neprilysin inhibitor
This article was originally published in Scrip
Novartis may be able to plug the gap in treatments for heart failure with preserved ejection fraction with its novel product LCZ696, based on positive effects on a surrogate marker in a Phase II trial presented this weekend at the European Society of Cardiology meeting in Munich.
You may also be interested in...
Entresto has narrowly failed to hit the primary endpoint in a Phase III trial in heart failure with preserved ejection fraction, a potentially lucrative indication with no approved treatments.
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.